Knight Therapeutics Inc. (KHTRF)
| Previous close | 4.2900 |
| Open | 4.1900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.1900 - 4.1900 |
| 52-week range | 3.2010 - 4.2900 |
| Volume | |
| Avg. volume | 6,874 |
| Market cap | 423.902M |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireKnight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com. About
- GlobeNewswire
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on Business magazine’s fifth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity. The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to
Simply Wall St.Knight Therapeutics Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Last week saw the newest full-year earnings release from Knight Therapeutics Inc. ( TSE:GUD ), an important milestone...
